Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Ascendis Pharma A (ASND) over the last 5 years, with Q4 2025 value amounting to $27.5 million.

  • Ascendis Pharma A's Cost of Revenue rose 8332.84% to $27.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $107.6 million, marking a year-over-year increase of 12490.16%. This contributed to the annual value of $107.3 million for FY2025, which is 12680.23% up from last year.
  • As of Q4 2025, Ascendis Pharma A's Cost of Revenue stood at $27.5 million, which was up 8332.84% from $26.1 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Cost of Revenue high stood at $35.6 million for Q2 2025, and its period low was $1.2 million during Q2 2022.
  • Over the past 5 years, Ascendis Pharma A's median Cost of Revenue value was $12.3 million (recorded in 2024), while the average stood at $13.0 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Cost of Revenue skyrocketed by 111491.34% in 2023, and later crashed by 2842.02% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Cost of Revenue (Quarter) stood at $4.0 million in 2021, then increased by 29.38% to $5.2 million in 2022, then surged by 301.47% to $20.9 million in 2023, then decreased by 28.42% to $15.0 million in 2024, then skyrocketed by 83.33% to $27.5 million in 2025.
  • Its Cost of Revenue stands at $27.5 million for Q4 2025, versus $26.1 million for Q3 2025 and $35.6 million for Q2 2025.